Literature DB >> 18503170

Immune reconstitution inflammatory syndrome among HIV/AIDS patients during highly active antiretroviral therapy in Addis Ababa, Ethiopia.

Kahsay Huruy1, Andargachew Mulu, Getahun Mengistu, Aster Shewa-Amare, Addis Akalu, Afework Kassu, Gashaw Andargie, Daniel Elias, Workineh Torben.   

Abstract

Suppression of viral replication is followed by increases in CD4+ lymphocytes, and this has been shown to result in decreased susceptibility to opportunists after initiation of highly active antiretroviral therapy (HAART). However, clinical aggravations after the initiation of HAART have been thought to be due to the restored ability to mount an inflammatory response, or the immune reconstitution inflammatory syndrome (IRIS). The degree of IRIS observed in human immunodeficiency virus (HIV)-infected patients following initiation of HAART is variable. This prospective study was aimed at determining the proportion of IRIS and the pattern of opportunistic infections among 186 HIV/AIDS patients receiving HAART between December 2006 and July 2007 at Zewditu Memorial Hospital, Addis Ababa, Ethiopia. The proportion of IRIS was 17.2% (32/186). The mean number of days of IRIS occurrence for each disease ranged from 26 to 122 days with a mean of 80. Opportunistic diseases associated with IRIS were tuberculosis (68.8%, 22/32), herpes zoster rash (12.5%, 4/32), cryptococcosis (9.4%, 3/32), toxoplasmosis (6.3%, 2/32) and bacterial pneumonia (3.1%, 1/32). Compared to baseline readings there were significant increases in CD4 count, aspartate aminotransferase and alanine aminotransferase levels while hemoglobin values decreased during the development of IRIS. In summary, the proportion of IRIS and the pattern of opportunistic infections in HAART-treated patients in Ethiopia mirrored those reported in other countries. Further prospective surveys on epidemiological, immunological, microbial and clinical studies are imperative to assess the proportion and pattern of IRIS and effect of HAART in Ethiopia.

Entities:  

Mesh:

Year:  2008        PMID: 18503170

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  19 in total

1.  Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome.

Authors:  Shuli Bonham; David B Meya; Paul R Bohjanen; David R Boulware
Journal:  Biomark Med       Date:  2008       Impact factor: 2.851

Review 2.  Immune restoration diseases reflect diverse immunopathological mechanisms.

Authors:  Patricia Price; David M Murdoch; Upasna Agarwal; Sharon R Lewin; Julian H Elliott; Martyn A French
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 3.  Immune reconstitution inflammatory syndrome-associated Burkitt lymphoma after combination antiretroviral therapy in HIV-infected patients.

Authors:  Prakash Vishnu; Russell P Dorer; David M Aboulafia
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-10-02

Review 4.  The immune reconstitution inflammatory syndrome related to HIV co-infections: a review.

Authors:  D Huis in 't Veld; H-Y Sun; C-C Hung; R Colebunders
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-02       Impact factor: 3.267

5.  Immune reconstitution inflammatory syndrome: incidence and implications for mortality.

Authors:  Richard M Novak; James T Richardson; Kate Buchacz; Joan S Chmiel; Marcus D Durham; Frank J Palella; Andrea Wendrow; Kathy Wood; Benjamin Young; John T Brooks
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

6.  Late-stage disease at presentation to an HIV clinic in eastern Tanzania: A retrospective cross-sectional study.

Authors:  H Mhozya; D Bintabara; S Kibusi; E Neilson; B C Mpondo
Journal:  Malawi Med J       Date:  2015-12       Impact factor: 0.875

7.  Immune reconstitution inflammatory syndrome in AIDS-related non-hodgkin's lymphoma.

Authors:  Uday A Phatak
Journal:  Indian J Med Paediatr Oncol       Date:  2009-10

8.  The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.

Authors:  Kogieleum Naidoo; Nonhlanhla Yende-Zuma; Nesri Padayatchi; Kasavan Naidoo; Niraksha Jithoo; Gonasagrie Nair; Sheila Bamber; Santhana Gengiah; Wafaa M El-Sadr; Gerald Friedland; Salim Abdool Karim
Journal:  Ann Intern Med       Date:  2012-09-04       Impact factor: 25.391

Review 9.  CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 2: discussion of neuro-immune reconstitution inflammatory syndrome with and without other pathogens.

Authors:  M J D Post; M M Thurnher; D B Clifford; A Nath; R G Gonzalez; R K Gupta; K K Post
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-12       Impact factor: 3.825

Review 10.  CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 1: overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal-immune reconstitution inflammatory syndrome.

Authors:  M J D Post; M M Thurnher; D B Clifford; A Nath; R G Gonzalez; R K Gupta; K K Post
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-12       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.